Pharma Reviews: With Vildagliptin off-patent from today, new doors open for pharma players

It is expected to start selling the drug for type-2 diabetes in the Indian market from today. Also Read: Eris Lifesciences acquires diabetes drug ...
Read more: With Vildagliptin off-patent from today, new doors open for pharma players